EAM Investors LLC acquired a new position in shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 144,022 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,471,000. EAM Investors LLC owned about 0.52% of Paratek Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in PRTK. C WorldWide Group Holding A S lifted its position in shares of Paratek Pharmaceuticals by 449.3% during the 2nd quarter. C WorldWide Group Holding A S now owns 439,400 shares of the specialty pharmaceutical company’s stock worth $10,590,000 after buying an additional 359,400 shares during the last quarter. Pictet Asset Management Ltd. bought a new stake in shares of Paratek Pharmaceuticals during the 2nd quarter worth $6,957,000. Renaissance Technologies LLC lifted its position in shares of Paratek Pharmaceuticals by 275.9% during the 1st quarter. Renaissance Technologies LLC now owns 414,513 shares of the specialty pharmaceutical company’s stock worth $7,979,000 after buying an additional 304,249 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of Paratek Pharmaceuticals by 106.8% during the 2nd quarter. Franklin Resources Inc. now owns 508,066 shares of the specialty pharmaceutical company’s stock worth $12,244,000 after buying an additional 262,374 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Paratek Pharmaceuticals by 1,898.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 199,725 shares of the specialty pharmaceutical company’s stock worth $4,813,000 after buying an additional 189,730 shares during the last quarter. Institutional investors and hedge funds own 82.33% of the company’s stock.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.89) by $0.25. The business had revenue of $7.51 million for the quarter, compared to analysts’ expectations of $7.50 million.

PRTK has been the subject of several recent analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $50.00 price objective on shares of Paratek Pharmaceuticals in a research report on Thursday, June 22nd. HC Wainwright upped their price objective on Paratek Pharmaceuticals from $36.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, July 18th. BidaskClub downgraded Paratek Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Zacks Investment Research upgraded Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a research report on Saturday, August 5th. Finally, Raymond James Financial, Inc. restated a “strong-buy” rating and set a $36.00 price objective on shares of Paratek Pharmaceuticals in a research report on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $37.44.

In other news, Chairman Michael Bigham sold 5,075 shares of the company’s stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $23.58, for a total value of $119,668.50. Following the completion of the transaction, the chairman now directly owns 109,500 shares in the company, valued at approximately $2,582,010. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Adam Woodrow sold 3,800 shares of the company’s stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $23.58, for a total value of $89,604.00. Following the completion of the transaction, the vice president now owns 69,500 shares of the company’s stock, valued at $1,638,810. The disclosure for this sale can be found here. Insiders sold a total of 17,365 shares of company stock valued at $409,467 over the last quarter. Company insiders own 4.90% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/09/25/eam-investors-llc-takes-3-47-million-position-in-paratek-pharmaceuticals-inc-prtk.html.

Paratek Pharmaceuticals Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.